Major Investment Alert: Zivo Bioscience Sees Significant Shareholder Action
I'm PortAI, I can summarize articles.
Mark E. Strome has invested $249,996 in Zivo Bioscience by acquiring 20,259 shares. However, Spark's AI Analyst rates ZIVO as an Underperform due to significant financial challenges, including negative equity and cash flow issues. The company requires urgent financial restructuring for sustainability, with a year-to-date price performance of -41.73% and a current market cap of $47.75M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments